Cholera Vaccine  Market By Vaccine Type (Oral Cholera Vaccines, {Dukoral, Shanchol, Euvichol}, Injectable Cholera Vaccines, Combination Vaccines), By Disease Type (Endemic Cholera, Epidemic Cholera, Traveler’s Cholera), By Technology  (Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vaccines), By End-User (Government and Public Health Organizations, Non-Governmental Organizations, Hospitals, and Clinics, Pharmaceutical and Vaccine Manufacturers), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Cholera Vaccine Market accounted for USD 94.8 Million in 2024 and is expected to reach USD 237.3 Million by 2035, growing at a CAGR of around 8.7% between 2025 and 2035. The cholera vaccine market defines the global market that deals in the manufacture, distribution, and sale of vaccines intended for the prevention of cholera disease, which is an acute diarrheal illness that is highly contagious and caused by Vibrio cholerae bacteria. These vaccines are particularly beneficial in populations with poor hygiene and limited access to clean water, where the disease is prevalent.

Currently, the market provides oral vaccines such as Dukoral and Shanchol, which are used for routine immunizations and outbreaks. Growing concern about watery illnesses, combined with containment measures in the global healthcare system, is propelling the cholera vaccine market, notably in Asia, Africa, and Latin America.

Report Scope:

Market Dynamics

Increasing incidence of cholera in endemic regions drives demand for vaccines

New cases of cholera, and also improvements in cholera-affected areas, have put pressure on producers to develop cholera vaccines. Rapid urbanization, population congestion, poor hygiene, and a lack of adequate potable water supply in disadvantaged communities all contribute to the disease's continuous spread. Furthermore, climate change, which impacts the frequency of rain and floods, influences the risk of cholera. As a result of these characteristics, governments, international organizations, and corporate players are focused on vaccine research and deployment as a means of prevention.

The World Health Organization has supported this policy reform because current estimates indicate that 1.3 to 4 million people are affected with cholera each year. According to the World Health Organization, more than a quarter of a million doses of cholera vaccine will be administered in 2023 as a result of big events. As more individuals focus on becoming inoculated, there is concern regarding the expansion of cholera prevention efforts.

Support from WHO and GAVI for cholera vaccination campaigns boosts market growth

Several factors have led to the growth of the cholera vaccine market, the most obvious of which is increased backing from global health organizations such as WHO and GAVI, who have declared cholera control by immunization, particularly in affected areas. The recent cholera outbreaks in places with poor water and sanitation infrastructure have increased the demand for vaccines.

Other market growth drivers include government financing and assistance targeted to combat the disease in affected and humanitarian crisis areas. New vaccines have hit the market that are less expensive, more effective in some cases, and easier to administer. Other factors driving market growth include an increase in cholera cases as a worldwide health concern and advancements in vaccine manufacturing procedures. Furthermore, by establishing and developing public-private partnerships, corporate and multinational collaborations are speeding up vaccination delivery to the targeted vulnerable groups.

Poor healthcare infrastructure in low-income regions restricts vaccine distribution.

The cholera vaccine market has several hurdles in underdeveloped nations with limited healthcare infrastructures. Shortages of healthcare services, substandard stores, and a lack of refrigerated facilities for vaccines are key barriers to delivery. The high cost of vaccines and insufficient financing for immunization in impoverished places limit the broad use of vaccines.

Moreover, supply chain concerns such as shipping delays in back-end locations can impede vaccination. It also poses a challenge to providing immunization in remote areas due to a lack of healthcare workers to give vaccines. These limitations, along with a lack of vaccination education in some societies and a reluctance to be immunized, stymie efforts to control cholera outbreaks in high-risk areas around the world.

Expansion to Emerging Markets and untapped regions in Africa and Asia present growth potential

The cholera vaccine market has immense potential, and similar products for clients in new parts of Africa and Asia might be extremely lucrative. These locations are still prone to cholera outbreaks, inadequate potable water sources, and high population density. Cholera remains widespread in India, Bangladesh, Nigeria, and numerous parts of Sub-Saharan Africa, making these areas critical for immunization.

The expanded growth of the public health care system and the increased recognition of governmental interests in the battle against illnesses should increase the demand for vaccines. Furthermore, new immunization efforts backed by the WHO and GAVI are expected to expand the vaccines' market reach. As more research is conducted to establish better and less expensive vaccinations, this market remains a tremendous opportunity for any health programs and commercial vaccine manufacturers to profit, which they may use to significantly grow their market.

Government Collaboration and partnerships for subsidized vaccine programs can increase coverage

Public-private partnerships for subsidized government programs offer opportunities for the cholera vaccine market. Governments can reduce the cost of vaccines for people living in cholera-affected areas by forming worldwide partnerships with other organizations and departments of health. In most situations, they aid with the delivery of vaccines to low-income groups, increasing immunization coverage, and preventing epidemics. In many underdeveloped nations, public-private collaborations can help improve vaccine efficacy, duration, and storage practices.

Further, they can encourage more people to get vaccinated, resulting in community-wide immunity and lower overall healthcare costs. The cholera pandemic, and the growing emphasis on global health equality and readiness for future outbreaks, has increased the demand for efficient cholera vaccines, creating a market expansion opportunity at the moment.

Industry Expert's Opinion:

“We expect our overall capability to produce oral cholera vaccine to increase to more than 50 million doses in 2024, to more than 70 million doses in 2025, and more than 90 million doses by 2026.”

• Rachel Park, director of international business at Eu Biologics in Seoul, South Korea.

Segment Analysis

Based on vaccine type, the cholera vaccine market is classified into Oral Cholera Vaccines, {Dukoral, Shanchol, Euvichol}, Injectable Cholera Vaccines, and Combination Vaccines. In the cholera vaccine market, oral cholera vaccines, or OCVs, such as Dukoral, Shanchol, and Euvichol, are the most popular. These vaccines are favored since they do not need to be administered by skilled staff. Oral vaccines are considerably less expensive to make, making them ideal for immunizing large populations in cholera-affected areas. Because of their efficiency, ease of giving immunity, and influence on disease management, their simplicity and efficacy propelled them to the top of the worldwide public health and cholera vaccine software market.

Based on disease type, the cholera vaccine market is classified into Endemic Cholera, Epidemic Cholera, and Traveler’s Cholera. Epidemic cholera is expected to be the largest category in the cholera vaccine market. There is also a societal side to the disease since it has been known to strike places with inadequate sanitation and water supply, resulting in a cholera outbreak. People in regions with recurring seasonal occurrences require immunizations most of the time because rapid response is required during outbreaks. These vaccinations are extremely crucial in avoiding large-scale epidemics, and governments and global health organizations ensure their availability during emergencies. This makes epidemic cholera the main targeted area for cholera vaccinations.

Regional Analysis

The MEA cholera vaccine market is slowly growing as cholera cases increase around the world, particularly in areas without access to potable water and basic sanitation. Currently, the greatest market is Sub-Saharan Africa, where cholera is still endemic, but Middle Eastern countries, despite being less frequently affected, use immunizations due to regional and international health concerns and frequent travel. Civil society organizations, particularly the World Health Organization, play essential roles in promoting immunization and ensuring equitable vaccine delivery around the world.

Increased awareness, government help, and commercial development have all been identified as possible vaccination breakthroughs. This results in challenges like political upheavals, insufficient health referee institutions, and disruptions in the vaccine supply chain, all of which impede market expansion. The market is formed by government and business sector efforts to establish and expand regional immunization programs.

The Asia-Pacific cholera vaccine market dominates due to the disease's ongoing vulnerability in nations lacking proper water sanitation and treatment facilities. Many countries, particularly in South Asia, such as India, Bangladesh, and Indonesia, have cholera epidemics on occasion, necessitating the usage of vaccinations. In recent years, the WHO has pushed the use of cholera vaccinations as part of integrated healthcare efforts. As a result of increasing awareness, governments have undertaken attempts to procure vaccines. Currently, there are OCVs on the market, such as Dukoral and Shanchol that provide greater coverage to at-risk groups. Other drivers include government health policies, international aid, and demand for a shift from curative to preventive healthcare.

Even though the market is rapidly expanding, the corporation continues to face hurdles such as a limited supply of vaccinations, delivery concerns, and public education on cholera. Furthermore, relations and cooperation with regional organizations, such as GAVI, continue to promote vaccination availability in disease-affected countries.

Competitive Landscape

The cholera vaccine market is saturated, with prominent players such as Valneva SE, Sanofi Pasteur, PaxVax Inc., Serum Institute of India, and Hilleman Laboratories. Valneva SE developed VLA Cholera, which is one of the top vaccines, while Sanofi Pasteur developed Oral Dukoral, another well-known oral vaccine. CholeraVax by PaxVax has also been a source of supply all over the world. In India, the Serum Institute plays a significant role in Euvichol, which has become a popular immunization in underdeveloped countries. The new threats and changes in the market include increased access to vaccines in low-income countries and the ongoing challenges of refining vaccines with greater efficacy and coverage for the world's various ailments, an area in which Hilleman Laboratories specializes in providing affordable and efficient solutions. These participants move on to policymaking, and the world hopes to see how they are reducing cholera mortality, particularly in endemic areas.

Cholera Vaccine  Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In April 2024, Eu Biologics Co., Ltd. announced that a new cholera vaccine, Eu vichol-S, had received WHO prequalification and is now made available to countries globally. According to UNICEF, the overall supply of oral cholera vaccines reached approximately 50 million doses in 2024 compared to 38 million doses in 2023. Therefore, this new product is anticipated to help Eu Biologics Co., Ltd. produce volumes of vaccines at a lower cost.
• In February 2023, Emergent BioSolutions Inc. entered a partnership with Bavarian Nordic. The company acquired the rights to the Vaxchora vaccine. In addition, it acquired Emergent’s manufacturing site in Bern, Switzerland, and other facilities in San Diego, California. Furthermore, it is declared that around 280 Emergent employees are expected to join the company.

Report Coverage:

By Vaccine Type

• Oral Cholera Vaccines
  • Dukoral
  • Shanchol
  • Euvichol
• Injectable Cholera Vaccines
• Combination Vaccines

By Disease Type

• Endemic Cholera
• Epidemic Cholera
• Traveler’s Cholera

By Technology

• Inactivated Vaccines
• Live Attenuated Vaccines
• Recombinant Vaccines

By End-User

• Government and Public Health Organizations
• Non-Governmental Organizations
• Hospitals and Clinics
• Pharmaceutical and Vaccine Manufacturers

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Valneva SE
• Sanofi Pasteur
• PaxVax, Inc.
• Serum Institute of India
• Euvichol
• Hilleman Laboratories
• GlaxoSmithKline (GSK)
• Johnson & Johnson
• Vabio tech
• China National Biotec Group (CNBG)
• Biovac Institute
• Merck & Co.
• Mylan Pharmaceuticals
• Intas Pharmaceuticals
• The Vaccine Initiative

Frequently Asked Questions (FAQs)